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Abstract
Novel biomarker assays and upgraded analytical tools are urgently needed to accurately
discriminate benign prostatic hypertrophy (BPH) from prostate cancer (CaP). To address
this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quanti-
tate prostate specific antigen (PSA; free and total), prostatic acid phosphatase, carbonic
anhydrase 1 (CA1), osteonectin, IL-6 soluble receptor (IL-6sr), and spondin-2. We used the
sensor to measure these seven proteins in serum samples from 120 benign prostate hyper-
trophy patients and 100 Gleason score 6 and 7 CaP using serum samples previously col-
lected and banked. The results were analyzed with receiver operator characteristic curve
analysis. There were significant differences between BPH and CaP patients in the PSA,
CA1, and spondin-2 assays. The highest AUC discrimination was achieved with a spondin-
2 OR free/total PSA operation—the area under the curve was 0.84 with a p value below
10−6. Some of these data seem to contradict previous reports and highlight the importance
of sample selection and proper assay building in the development of biomarker measure-
ment schemes. This bead-based system offers important advantages in assay building
including low cost, high throughput, and rapid identification of an optimal matched antibody
pair.
Introduction
Prostate cancer (CaP) is the second leading cause of cancer death in US men, yet effective
screening and prognostication tools have remained elusive due to non-specific assays and bio-
markers [1]. While enzyme-linked immunosorbent assay (ELISA) is the gold standard for mea-
suring serum proteins, it suffers from long assay development times for new biomarkers, high
PLOSONE | DOI:10.1371/journal.pone.0139484 September 30, 2015 1 / 15
OPEN ACCESS
Citation: Jokerst JV, Chen Z, Xu L, Nolley R, Chang
E, Mitchell B, et al. (2015) A Magnetic Bead-Based
Sensor for the Quantification of Multiple Prostate
Cancer Biomarkers. PLoS ONE 10(9): e0139484.
doi:10.1371/journal.pone.0139484
Editor: Chandan Kumar-Sinha, University of
Michigan, UNITED STATES
Received: January 22, 2015
Accepted: September 13, 2015
Published: September 30, 2015
Copyright: © 2015 Jokerst et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the USA
National Cancer Institute Grant U01 CA152737, R25-
T CA118681 and the Canary Foundation. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
sample volumes, and requires many complicated operating steps. ELISA also can suffer from
high background and non-specific interferences because it uses an optical-based reporting
scheme.
To solve this, many competing technologies have been proposed including chemilumines-
cent-, microfluidic- [2], nanotechnology- [3], and magnetic-based [4] approaches. However,
many of these approaches suffer from high cost, low throughput, long assay construction
times, and the need for a skilled operator. Thus, a powerful but simple assay platform with uni-
versal utility for a broad variety of protein biomarkers has yet to be reported. In particular, the
biomarker community would be well served by analytical tools for panels of biomarkers.
Indeed, several recent studies have suggested that panels of biomarkers may be more effec-
tive at the early identification of cancer and classification of disease aggressiveness than the
prostate specific antigen [5] or other single point assays [6, 7]. Indeed, due to the deep biologi-
cal complexity of cancer, it does seem logical that assaying for more than one biomarker would
be beneficial in accurately prognosticating or detecting disease in the highest number of
patients. These panels include transmembrane proteins [8], metabolites [9], auto-antibodies
[10], non-coding RNA such as PCA3 [11], gene fusions including TMPRSS2-ERG [12], circu-
lating tumor cells [13, 14], DNAmethylation patterns [15], gene profiling [16], exosomes/pros-
tasomes [17], and many others [18].
Here, we describe a piezoelectric membrane-based approach that uses specific interactions
with magnetic beads to quantify prostate cancer biomarkers with many advantages for assay
building: 1) This approach is nearly matrix-free because it uses magnetic- and piezo-based
quantification schemes rather than optics; 2) The system can rapidly (<2 days) identify a
matched antibody pair for immunoassay; 3) The system has detection limits log orders lower
than ELISA because of the avidity of the three dimensional bead versus planar ELISA; and 4)
The system is largely operator-independent.
We used this tool to create a prostate cancer biomarker panel and evaluated its utility from
samples from CaP patients and patients with benign prostatic hypertrophy (BPH). We focused
on serum proteins due their ease of sampling, established role in disease identification and
monitoring, and the large number of banked serum samples available for testing. We included
newly identified markers as well as established PSA-based tests. Seven proteins were included
in this panel based on the current literature understanding of CaP:
• PSA [5] is an enzymatic glycoprotein produced by the prostate with function in sperm motil-
ity [7]. This panel includes both free PSA (fPSA) uncomplexed to chaperone carbohydrate
proteins and total PSA (tPSA) that includes both complexed and uncomplexed isomers [19,
20].
• Prostatic acid phosphatase (PAP) is a 100 kD glycoprotein synthesized in the prostate that
hydrolyzes phosphate esters at acidic pH. PAP is documented in the historical literature and
was used prior to the identification of PSA to detect and monitor CaP [21]. Panels utilizing
PAP have shown increased specificity, but no increase in sensitivity [22].
• Carbonic anhydrase 1 (CA1) is a metalloenzyme implicated in the interconversion of dis-
solved CO2 and water into bicarbonate and is responsible for pH regulation. CA1 has
recently been shown to be up-regulated in CaP patients through mass spectrometric profiling
[23].
• Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or base-
ment-membrane protein 40 is a 40 kD protein implicated in the migration of prostate cancer
cells [24] and metastatic prostate cancer [25].
Serum Biomarker Panel for Prostate Cancer Detection
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• Interleukin-6 (IL-6) is an inflammatory cytokine. IL-6 and its ligand IL-6 soluble receptor
(IL-6sr) are correlated with aggressive disease, including higher Gleason score, advanced
stage, development of metastasis and decreased survival [26, 27]. Circulating levels of both
IL-6 and IL-6sr are thought to result from the primary tumor as opposed to metastatic depos-
its [7].
• Spondin-2 (SPON2) works with the Wnt pathway to activate beta catenin and may facilitate
morphogenesis [28]. SPON2 has been shown to be overexpressed in tissue culture media of
androgen receptor positive prostate cancer cell lines [29, 30]. SPON2 serum tests were also
shown to be elevated in patients with CaP relative to healthy controls [31].
This magnetic bead-based system correlates the concentration of biomarker to changes in
acoustic frequency of a piezo-electric membrane [32]. The linear dynamic range of the assay
was tuned to match the relevant concentration of these biomarkers in diluted serum [33]. We
first identified matched antibody pairs and then characterized the assays for reproducibility,
analytical sensitivity, and matrix interferences. We finally examined the clinical sensitivity and
specificity of the panel with a retrospective trial of 240 banked human serum samples. To the
best of our knowledge, this is the first example of these proteins integrated into a single panel
and the most detailed use of this bead-based piezoelectric analysis system with important
implications in CaP screening, monitoring, and treatment.
Materials and Methods
Antibodies
Unless otherwise stated, immunoreagents were functionalized in our lab and validated with either
a recombinant or patient-purified protein standards. Optimal matched pairs including capture
antibody (c.Ab) and detecting antibody (d.Ab) were obtained from the following vendors:
• tPSA: The c.Ab (Meridian p/n M66280M) the d.Ab (Meridian p/n M66276M) were both
mouse monoclonal IgG.
• fPSA: The c.Ab (Meridian p/n M86806M) the d.Ab (Meridian p/n M66276M) were both
mouse monoclonal IgG. For both tPSA and fPSA we used native human PSA prepared in our
laboratory as the standard [34].
• PAP: The c.Ab (CosmoBio p/n SIM-2ZHCMP2-EX; clone Hyb-7432, described below as
Cos2) was a mouse monoclonal, and the d.Ab (CosmoBio p/n SIM-2ZHCMP1-EX, described
below as Cos1) was a mouse monoclonal. A recombinant protein standard (Fitzgerald p/n
30C-CP1016x) validated the assay. Other antibodies evaluated include a mouse monoclonal
IgG1 clone 690017 from R&D Systems (RDMo) and a sheep polyclonal IgG p/n AF6249
from R&D Systems (RDPo).
• SPARC: The c.Ab (Invitrogen; p/n 33–5500 (On1-1)) was a mouse monoclonal, and the d.
Ab (R&D Systems; p/n AF941) was a goal polyclonal. A recombinant protein standard (R&D
Systems p/n 941-SP-050) validated the assay.
• CA1: The c.Ab (Abnova; p/n H00000759-M21) was a rabbit affinity-purified polyclonal, and
the d.Ab (Abnova; p/n H00000759-D01P) was mouse monoclonal anti-CA1, IgG2b Kappa.
A recombinant protein standard (Abnova p/n H00000759-P01) validated the assay.
• IL6-sr: The c.Ab (R&D Systems p/n AF227) was a goat polyclonal, and the d.Ab (R&D Sys-
tems p/n MAB227) was a mouse monoclonal. A recombinant protein standard validated the
assay.
Serum Biomarker Panel for Prostate Cancer Detection
PLOS ONE | DOI:10.1371/journal.pone.0139484 September 30, 2015 3 / 15
• SPON2: The c.Ab (R&D Systems p/n AF2609) was a goat polyclonal, and the d.Ab (Abnova
p/n H00010417-MO1J) was a mouse monoclonal. A recombinant protein standard (R&D
Systems) validated the assay.
Assay Reagents
Magnetic beads and d.Abs were prepared as described previously [35]. Briefly, beads (1 mg,
Bioscale, Inc.) were stored in anhydrous dimethylformamide and were collected by centrifuga-
tion and washed with PBS. After the last wash, we added PBS, 146 μL 4.1 M ammonium sulfate,
and 5–20 μg of antibody. The amount of PBS was adjusted such that total volume was 300 μL.
The solution was incubated overnight on a tube rotator turning at 4 rpm. The next day, the
solution was washed four times with 0.1% Tween in PBS (PBST) and finally stored in PBS with
1% BSA and 0.01% sodium azide. Beads were stable for over 4 months.
The d.Abs were labeled with a NHS-fluorescein reagent (Pierce). The dye was added at a
20-fold molar ratio and incubated at room temperature in PBS at room temperature while pro-
tected from light. The conjugate was purified with spin columns and characterized with
absorption spectroscopy to determine the final concentration and labeling efficiency.
Analyzer and Assay Conditions
We used a commercially available piezo-electric analyzer for the protein measurements
(VIBE, Bioscale, Inc.; see S1 Video). This system consists of a bench top analyzer and dis-
posable reagent cartridge capable of analyzing 288 specimens and standards per run. The
analyzer has embedded fluid handling, waste disposal, and data handling capabilities [33,
35]. Signal is reported in relative units via embedded software and is proportional to the
number of beads immobilized on the membrane and thus analyte concentration. Hardware
control and data analysis was performed with Bioscale commercial software (Vibe version
0.7.3).
This system consists of a disposable 8-channel cartridge connected to fluidic handling
robotics and an electrically controlled magnet. Samples and standards were prepared at 1:10–
1:1000 dilution factor and plated into 96 well plates along with beads and fluorescent antibody.
The specimens were prepared by mixing 80 μL of sample or standard with 20 μL of beads
coated with c.Ab (900,000 beads/mL) and 20 μL of fluorescein-labeled d.Ab (1200 ng/mL).
These reagents form an immunocomplex sandwich in the presence of the biomarker antigen
(Fig 1A).
Up to 100 μL of this mixture was required for magnetic sorting and analysis. This mixture
was incubated with shaking for 4 hours. The solution in each column of the plate (all 8 wells)
was then auto-pipetted into individual flow channels within the 8-channel cartridge. After the
solution was loaded into the chamber, a magnetic field was applied and all beads were drawn
towards the anti-fluorescein IgG-coated piezo membrane in front of the magnetic field. Flow
and dilution factors were adjusted such that the number of immobilized beads was between
2000–3000.
As these beads come into contact with this piezo membrane, the oscillation frequency is
altered and recorded (Fig 1B). The magnetic field was maintained to allow interactions between
beads with complete immunocomplexes and the membrane—the fluorescein tag on the d.Ab
facilitated binding of the immunocomplex to an anti-fluorescein IgG on the piezo membrane.
The field was then discontinued and flow resumed to remove non-specifically bound beads.
The change in piezo frequency was then recorded as a measure of the number of bound beads
and thus antigen concentration that completes the immunocomplex (Fig 1B).
Serum Biomarker Panel for Prostate Cancer Detection
PLOS ONE | DOI:10.1371/journal.pone.0139484 September 30, 2015 4 / 15
Samples
Banked serum samples had been collected over 20 years with informed consent by the Urology
Department at Stanford University. We used serum because it has clotting factors removed,
which can produce non-specific signal and background in plasma protein assays. Diagnosis
was confirmed with 10- or 12-core biopsies at the time of sample collection. The Internal
Review Board of Stanford University approved this study and the design of the informed con-
sent. All participants provided written informed consent at the time of sample collection, and
participant consent forms were curated along with the specimens at the Stanford Department
of Urology. These samples were thawed, de-identified, diluted in PBS, and aliquoted for testing.
We studied 240 samples selected at random from a bank of ~2,200 specimens curated at Stan-
ford Radiology. The average age of the BPH controls was 65.9 ± 9.2 (30–87), and the average
age for the CaP patients was 62.6 ± 6.4 (46–77); there was a statistically significant age differ-
ence between the two groups (p = 0.002). We have included this information in the text. There
were 120 BPH samples and 100 cases of confirmed prostate cancer selected; all samples had
PSA values between 2–20 ng/mL. Of the CaP samples, 32 were Gleason score 6 and 68 were
Gleason score 7. As a control, there were also 20 samples from men with CaP collected after
radical prostatectomy. Dilution factors were optimized empirically to give a spike recovery of
100% ± 10%. Pooled normal female serum was purchased from Atlanta Biologicals.
Fig 1. Detection Scheme. A. The c.Ab. is covalently bound to a magnetic bead that is incubated with sample and fluorescein-tagged d.Ab. This sample is
introduced into a flow cell capped with a piezo-electric membrane coated with an anti-fluorescein antibody. An electromagnet above the membrane is
controlled with embedded software. B. Upon magnetic perturbation, all beads (black circles) move towards the membrane (Bi), and beads with a completed
immunocomplex (black circles coated with red dots) bind to the anti-fluorescein antibody (Bii). After the field is removed and flow restored, only beads with a
completed immunocomplex remain bound (Biii). These beads alter the oscillation of the membrane (represented as orange sinusoidal curve), which is
interpreted as signal in arbitrary units [36]. See S1 Video. In B, the solid blue line labeled Pos refers to beads in the presence of antigen, and the dotted red
line labeled Neg refers to beads in the absence of antigen.
doi:10.1371/journal.pone.0139484.g001
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Data Interpretation and Statistics
Signal units of the unknowns were converted into concentration units using a standard sigmoi-
dal curve with Bioscale software (Vibe version 0.7.3). The detection range was defined as those
calibration points that could be discriminated from their next nearest calibration points. Refer-
ence ranges were taken from clinical guidelines or the literature depending on the status of the
biomarkers. We did a 2-tailed Student’s t test to compare the results of BPH and CaP samples
in Excel 2010. The AUC and ROC curves and associated statistics were prepared with Graph-
Pad Prism 6.04.
Results
Identification of Matched Pair
We first had to identify an optimal antibody pair, and the following section describes this
approach using PAP as an example—results for other assays are presented in Table 1. Fig 2
shows representative data of how this was achieved for the PAP biomarker with a so-called
“checkerboard assay.”Here, four different PAP antibodies as well as an isotype control were
used as both the c.Ab and d.Ab. All four antibodies and an isotype control was used at antigen
concentrations of 0 and 1 ng/mL. Fig 2A plots the signal difference between these two concen-
trations. For PAP the highest signal was with the Cos1 d.Ab and Cos2 c.Ab with a signal of
0.65 a.u. (Fig 2A). Inverting the order, i.e. Cos2 d.Ab and Cos1 c.Ab had a value of 0.43 a.u.
The pair from R&D Systems had lower signal, and the isotope control antibody had signal
<0.01 a.u. Thus, Cos1 and Cos2 were used for the remainder of the experiments.
Of course, changing the antibody pair changes the sensitivity of the curve. Fig 2B illustrates
that by changing the c.Ab to RDPo and the d.Ab to RDMo, the sensitivity range changed from
0.01–1.0 ng/mL to 1 to 100 ng/mL. Finally, we compared the response curves of PAP via the
bead-based system with ELISA using the same Cos1/Cos2 pair (Fig 2D). We show a 3-log
order improvement in analytical sensitivity using the bead-based approach that highlights the
enhanced analytical sensitivity due to avidity of the bead versus the planar ELISA substrate.
The amount of c.Ab and d.Ab per assay was also investigated (S1 Fig). The manufacturer
recommended a bead working concentration of 150,000 beads/mL and 200 ng/mL d.Ab. We
tested d.Ab values of 100 and 400 ng/mL as well as 10,000–300,000 beads/mL, but did not find
any enhancement in dose-dependent curve from 10.0 to 0.015 ng/mL. At 1 ng/mL of recombi-
nant standard PAP, the highest signal was achieved with 10,000 beads/mL and 100 ng/mL of d.
Ab. However, these conditions also resulted in higher background signal at lower
Table 1. Optimized assay parameters. The best-matched pair with resulting dynamic range, reference range, and dilution factors are shown for the 7 bio-
marker assays as well as representative intra-assay variation values.
Biomarker # Ab.
Tested
Detection Ab. Capture Ab. Range
(ng/mL)
Reference
(ng/mL)
Dilution
Factor
%
CV
tPSA 4 M66276M (Meridian) M66280M (Meridian) 0.04–50 < 4 1:5 0.69
Free/Total
PSA
4 M66276M (Meridian) M86806M (Meridian) 0.01–10 5–30% of
tPSA
1:5 0.80
PAP 4 SIM-2ZHCMP1-EX
(CosmoBio)
SIM-2ZHCMP2-EX
(CosmoBio)
0.01–10 <2.1 1:20 0.51
SPARC 3 AF941 (R&D) 33–5500 (Invitrogen) 5–4000 <2000 1:20 0.51
CA1 4 H00000759 D01P (Abnova) H00000759 M21 (Abnova) 0.1–50 <1000 1:300 0.55
IL-6sr 4 MAB227 (R&D) AF227 (R&D) 0.15–10 <25 1:50 0.57
SPON2 2 H00010417-M01J (Abnova) AF2609 (R&D) 0.38–
390
n/a 1:5 0.76
doi:10.1371/journal.pone.0139484.t001
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concentrations (S1 Fig). Thus, 150,000 beads/mL and 200 ng/mL d.Ab were used for all subse-
quent assays.
Assay Characterization
We next examined both intra-assay (between wells run on the same day at the same time) and
inter-assay variance (difference between the average of runs on different days; Fig 2C). For
PAP, intra-assay variance ranged from 0.05% relative standard deviation [37] at 6 ng/mL to
5.47% at 0.02 ng/mL. The inter-assay variance on three different days was 7.1% RSD. All other
assays had<7% variance for intra-assay variance and<10% for inter-assay variance. When
making day-to-day comparisons it was critically important that the calibration curves be
arranged in the 96-well plates the same way on each subsequent day. Because each row in the
96 well plate takes ~5 minutes to analyze, altering the location of the beads allows for longer
incubation times, which can result in higher bead/immunocomplex accumulation and thus
higher signal.
With an optimized matched antibody pair in hand, we next uncovered and corrected any
matrix interferences again illustrating with PAP. We used pooled normal female serum that
should contain no PAP. Serum at dilution factors from 1:2–1:256 was prepared and analyzed.
Another batch of diluted samples was spiked with 0.5 ng/mL PAP. The samples were analyzed
and the percent recovery plotted in Fig 3A as well as spike recovery data for SPARC spiking at
Fig 2. Assay Construction. A)Optimal antibody pairs were identified with a “checkerboard” assay that evaluated different antibody pairs as well as isotype
controls. Metric plotted here is signal difference between the negative control and 1 ng/mL recombinant PAP. The different antibodies are defined in the
Materials and Methods section.B) A full calibration curve illustrates the different sensitivities of different antibody pairs for PAP. Pair 1: Cos2 c.Ab.; Cos1 d.
Ab. Pair 2: RDPo c.Ab.; RDMo. d.Ab. The red error bars represent the standard deviation of at least three replicate measurements. C)Reproducibility from
day to day is <8%. D) The piezo-based approach shows 3 log orders improvement in analytical sensitivity versus direct ELISA when identical antibody pairs
are used (Cos1/Cos2).
doi:10.1371/journal.pone.0139484.g002
Serum Biomarker Panel for Prostate Cancer Detection
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125 ng/mL and CA1 spiking at 10 ng/mL. The results showed that 100% recovery was achieved
with 16-fold dilution factors for these analytes. Decreased and increased spike recovery values
are due to non-specific binding of other serum proteins to the antibodies. The other five bio-
markers were optimized similarly.
Clinical Samples
The first step was to validate sample stability. To do this, we reanalyzed the PSA values of a
subset (N = 35) of the samples that had high volumes of serum using a Beckman Access clinical
analyzer (Hybritech) at the Stanford University Medical Center and compared this to the val-
ues originally measured at the time of collection. We created a Bland-Altman plot and showed
that 92% of the samples were within the 95% confidence interval (Fig 3B). This validation only
used those samples that had enough volume for both the clinical system and bead-based assay.
The results indicated that the PSA integrity was maintained during storage.
Next, we measured biomarker levels of all analytes in serum diluted to the concentrations
shown in Table 1. The data for the BPH, CaP, and post-surgery CaP samples are shown in Fig
4. The average value from CaP patient samples are 1.5-, 1.6-, 0.83-, 0.94-, 0.79, and 1.03-fold
higher than BPH for the CA1, PSA, IL6-sr, PAP, and SPARC assays, respectively. Tests with a
significant difference between BPH and CaP were PSA (p<0.0001), CA1 (p = 0.03), SPARC
(p = 0.049), and SPON2 (p<0.10−6).
We created ROC curves and measured the AUC for all biomarkers using the biopsy-con-
firmed diagnosis and measured values (Fig 5). The PAP AUC was 0.51; 95% confidence inter-
val 0.43–0.58 with p>0.50. The SPARC AUC was 0.51; 95% confidence interval 0.43 to 0.59
with p>0.50. The CA1 AUC was 0.55; 95% confidence interval 0.47 to 0.63 with p = 0.17. The
IL-6sr AUC was 0.57; 95% confidence interval 0.50 to 0.65 with p = 0.06. The SPON2 AUC
was 0.76; 95% confidence interval 0.69 to 0.82 with p<0.0001.
The AUC value for PSA is typical of literature values [40–42]. In one meta-analysis using
free and total PSA, the aggregate for 41 studies with 19,643 participants was an AUC of 0.70
[41]. Unfortunately, other biomarkers did not improve the AUC with the exception of SPON2.
That marker had an AUC value of 0.76 compared to the PSA AUC of 0.80. When the two were
used in an OR operation, the AUC increased slightly 0.84. No other operations or other combi-
nations of biomarkers increased the AUC curve.
We also studied whether any biomarkers could discriminate between Gleason 6 and Glea-
son 7 patients (S1 Table). None of the novel proteins showed a p value<0.05. While this data-
set did show a very significant difference for tPSA (<0.01), this is likely due to the presence of
some outlier values—the p value was 0.06 when we used the original clinical PSA values. We
also did ROC analysis for different Gleason scores versus BPH and noted significance with IL-
6sr. In comparing Gleason 7 patients versus BPH with IL-6sr, we found an AUC value of 0.66;
the 95% confidence interval was 0.57 to 0.76 with p = 0.005. Segregating by Gleason score did
not improve the AUC values for other biomarkers.
Discussion
There are many approaches to measuring novel CaP biomarkers beyond traditional ELISA.
One of the fundamental bottlenecks in most assay development schemes is the identification of
a suitable matched antibody pair. This is perhaps the most important advantage of the bead
based approach used in the current work—the identification of a matched antibody pair usu-
ally takes less than 2 days from the synthesis of the reagents to the final selection of the optimal
pair. This system has good inter- and intra-assay reproducibility (CV<10%) and can quickly
minimize matrix interferences. Other advantages include the lower detection limits because of
Serum Biomarker Panel for Prostate Cancer Detection
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Fig 3. Serum Validation. A) Percent recovery for three representative biomarkers. Matrix effects can either dampen signal (CA1, PAP) or inflate signal
(SPARC). Ideal dilution factors were dependent on sensitivity of the assay and reference range of the biomarker (Table 1). Black dashed line indicates 100%
spike recovery.B) Bland-Altman plot [38] validating specimen integrity of a subset (N = 35) of the clinical samples with high sample volumes. Red dashed line
indicates 95% confidence interval.
doi:10.1371/journal.pone.0139484.g003
Serum Biomarker Panel for Prostate Cancer Detection
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Fig 4. SerumData.Raw values with means for BPH, CaP, and post-surgery (PS) samples. Biomarkers include tPSA (A), fPSA(B), CA1 (C), PAP (D), IL6-sr
(E), SPARC (F), and SPON2 (G). Horizontal lines indicate mean values.
doi:10.1371/journal.pone.0139484.g004
Serum Biomarker Panel for Prostate Cancer Detection
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avidity in the bead design as well as low threshold for user training. Limitations of the system
include the relatively high sample volume requirements because of restricted multiplexing. To
solve this, we are developing additional analytical tools in our labs such as the magneto-nano-
sensor for multiplexed analyses with large dynamic ranges and low sample volume (40 μl)
requirements critical for precious samples [4].
It is important that biomarker verification be allowed to fail quickly before significant invest-
ments are made in test development or use of precious clinical samples. This bead-based scheme
Fig 5. Clinical Data Analysis. A) Mean values with standard deviation for the seven biomarkers with BPH, CaP, and post-surgery [39] samples. Units are
ng/mL. The p value reported here is the significance between the BPH and CaP samples. AUC values are also given and report discrimination between CaP
and BPH. Lower panel presents ROC curves for PSA, SPON2, and PSA OR SPON2. The OR operator increases the AUC to 0.84 from 0.80 for PSA alone.
doi:10.1371/journal.pone.0139484.g005
Serum Biomarker Panel for Prostate Cancer Detection
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allows rapid verification of biomarker potential. Our data shows that many of the protein bio-
markers reported previously to discriminate between CaP and BPH patients failed with our spe-
cific patient samples. Perhaps most surprisingly was CA1. In previous work using 54 CaP
samples and 60 healthy controls [23], this protein had an AUC value of 0.64 and an AUC value
of 0.76 when combined with PSA. One important difference is in that study restricted their sam-
ples to patients in the so-called “grey zone” of PSA testing—PSA values between 4 and 10 ng/mL.
IL-6sr has also been shown to correlate with progression [27] and bone metastasis [26] and it
was plausible that differential expression would have been measured in BPH versus CaP patients
samples, however we noted no significant difference between these two patient populations.
Our work with SPON2 shows that it does have some utility in CaP testing. One curious fea-
ture from this study is that the levels in BPH patients (126.5 ng/mL) was actually higher than
CaP patients (73.0 ng/mL). This difference was very significant at p =<10−6. In a previous
paper [31], SPON2 levels in CaP patients (77.5 ng/mL) were higher than in patients with “no
evidence of malignancy” (23.6 ng/mL). While the differences in absolute values are likely
attributable to differences in standard and antibody selection, the trend is somewhat confusing.
One possible explanation is in patient selection differences. These normal healthy controls are
a much different patient cohort than the BPH group used for comparison in our study. Indeed,
it is possible that SPON2 levels increase during BPH above values seen in either normal or CaP
subjects. Future work will have to further study SPON2 levels in multiple patient and control
groups with high numbers of patients to better understand these discrepancies.
Another study suggested that SPON2 is only applicable to patients with PSA values below
10 ng/mL [30]. Restricting our samples to these patients gave a mean BPH value of
119.9 ± 65.9, a mean CaP value of 82.6 ± 50.36 (p = 0.004) and AUC of 0.72. Thus, restricting
our data to these patients did not improve the AUC.
Analysis of the post-surgery patients showed that the most dramatic changes in biomarker
levels occurred in PSA-based tests. The tPSA in post-prostatectomy patients decreased 18-fold
versus BPH and 30-fold for the CaP patients. PAP levels in the post-prostatectomy patients
was 2- to 3-fold lower. Other biomarkers showed no significant (P>0.05) change.
Conclusion
We report a piezoelectric bead-based sensor to measure serum proteins with potential to dis-
criminate between BPH and CaP. This study reconfirmed the use of PSA to discriminate
between BPH and CaP, but the AUC values were sub-optimal for population-wide screening.
We also showed that using SPON2 in tandem with PSA via an OR operation can increase the
AUC from 0.80 to 0.84. This approach has utility for a variety of circulating biomarkers and
future work will evaluate more promising biomarkers as well as urine-based biomarkers such
as the TMPRSS2:ERG fusion.
Supporting Information
S1 Fig. Optimization of Bead and d.Ab Concentration. Variations in d.Ab concentration
two-fold above and below the recommended 200 ng/mL value were used in addition to increas-
ing concentrations of beads (inset). Calibration curves at each of these points illustrate that the
response is stable ± 15% despite these variations.
(PDF)
S1 Table. Biomarker Concentrations as a Function of Gleason Score. PSA showed the most
significant differences between patients with Gleason scores of 6 and 7.
(PDF)
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S1 Video. Mechanisms of Action of the Bead-based Analyzer. This video illustrates the assay
parameters and shows how piezo-based signaling is translated to concentration of biomarker.
Reprinted from BioScale Inc under a CC BY license, with permission from BioScale Inc, origi-
nal copyright 2011.
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